Hypochlorous acid - Realm Therapeutics

Drug Profile

Hypochlorous acid - Realm Therapeutics

Alternative Names: PR-013; PR-022

Latest Information Update: 15 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Puricore
  • Developer Realm Therapeutics
  • Class Anti-inflammatories; Chlorine compounds; Eye disorder therapies; Noncarboxylic acids; Oxides; Reactive oxygen species; Skin disorder therapies; Small molecules
  • Mechanism of Action Immunomodulators; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Atopic dermatitis
  • Preclinical Dry eyes; Psoriasis
  • Discontinued Allergic conjunctivitis

Most Recent Events

  • 12 Mar 2018 Discontinued - Phase-II for Allergic conjunctivitis (In adolescents, In children, In the elderly, In adults) in USA (Ophthalmic) due to lack of efficacy
  • 12 Mar 2018 Preclinical trials in Dry eyes in USA (Ophthalmic) (Company pipeline)
  • 27 Feb 2018 Realm therapeutics receives notice of patent allowance for PR 013 and PR 022 from the USPTO
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top